参考文献/References:
1 Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer[J].Eur J Cancer, 1999, 35(3):867-885.
2 Weiner DB, Kennedy RC. Genetic vaccines[J]. Sci Am, 1999, 281(1):50-70,
3 Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line[J]. J Clin Endocrinol Metab, 1998, 83(11):3668-3672.
4 Blagosklonny MV, Giannakokou P, Wojtowics M, et al. Effects of p53-expression adenovirus on the ehemosensitivity and differentiationofanaplasticthyroidcancercells[J]. JClin Endocrinol Metab,1998, 83(8):2516-2522.
5 Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells[J]. Cancer Res, 2001, 61(11):3640-3646.
6 Kitazono M, Chuman Y, Aikou T, et al. Adenovirus HSV-TK construct with thyroid-specific promoter:Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway[J]. Iht J Cancer, 2002, 99(2):453-459.
7 Zahng R, De Groot IJ. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model:relationship of bystander effect and antitumor efficacy[J]. Thyroid, 2000, 10(1):313-319.
8 Zhang R, De Groot IJ. An adenoviral expression functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma[J]. Endocrinol Relat Cancer, 2001, 8(2):315-325.
9 Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor specific expression of intedeukin-12[J]. Gene Therapy,2002, 9(1):64-74.
10 Soler MN, Bobe P, Benihoud K, et al. Gene therapy of rat medullary thyroid cancer by naked nitric o. xide synthase Ⅱ DNA injection[J]. J Gene Med, 2000, 2(2):344-352.
11 Zhang R, De Groot LJ. Genetic immunotherapy of established tumors with adenoviral vectors transducing murine interleukin(mIL-12) subunits in a rat medullary thyroid carcinoma model[J]. Clin Endocrinol(Oxf), 2000, 52(3):687-694.
12 Zhang R, Straus FH, De Groot LJ. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin2:dissemination and cytotoxicity studies in a rat tumor model[J].Endocrinology, 1999, 140(7):2152-2158.
13 Filletti S, Bidart JM, Arturi R, et al. Sodium/Iodide symporter:a key transport system in thyroid cancer cell metabolism[J]. Eur J Endocrinol, 1999, 141(2):443-457.
14 Venkataraman GM, Yatin M, Mareinek R, et al. Restoration of iodine uptake in dedifferentiated thyroid carcinoma relationship to human Na+/I- symporter gene methylation status[J]. J Clin Endocrinol and Metab, 1999, 84(8):2449-2460.
15 Haupt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against the tumor associated antigen calcitolin by geneticimmunization[J]. J Endocrinol Investig, 1999, 22(supple):4.
16 Juweid ME, Hajjar G, Swayne LC, et al. Phase Ⅰ/Ⅱ trial of 131I-MN14F (ab)2 anticarcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma[J].Cancer, 1999, 85(6):1828-1842.
17 Simon D, Kohrle J, Reiners C, et al. Redifferentiation therapy with retinoids-a therapeutic option in advanced follicular and papillary thyroid carcinoma[J]. World J Surg, 1998, 22(2):569-574.
18 Simon D, Kohrle J, Reiners C, et al. Redifferentiation therapy in thyroid cancer-results of a multicenter pilot study[J]. Thyroid, 1998,8(4):1217.
19 Schmutaler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer[J]. Eur J Endocrinol, 2000, 143(1):15-24.
20 Signore A, Annovazzi A, Chianelli M, et al. Peptide radio-pharmaceuticals for diagnosis and therapy[J]. Eur J Nucl Med, 2001, 28(5):1555-1556.
21 Oberg K. Established clinical use of octreotide and lanreotide in oncology[J]. Chemotherapy, 2001, 47(1):47-63.
22 Weiner RE, Thakur ML. Radilabaled peptides in the diagnosis and therapy of oncological disease[J]. Appl Radiat Isot, 2002, 57(2):749-763.
23 Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging[J].Semin Nucl Med, 2002, 32(1):84-91.
24 Lamberts SWL, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer[J]. Trends Endocrinol Metab,2002, 13(2):451-502.
25 Papotti M, Kumar U,Volante M, et al. Immunohistochemical detection of somatostatin types 1-5 in medullary carcinoma of the thyroid[J]. Clin Endocrinol, 2001, 54(2):641-649.
26 Slooter GD, Mearadji A,Breeman WAP, et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumors[J]. Br J Surg, 2003, 88(1):31-40.
27 Boerman OC, Oyen WJG, Corstens FHM. Radio-labeled receptor binding peptides:a new class of radiopharmaceutical[J]. Semin Nucl Med, 2001, 30(1):195-208.
28 Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy[J]. J Nucl Med, 2002, 41(6):1704-1713.
29 Bugal JE, Erion JL, Johnson MA, et al. Radiothapeutical efficacy of 153-Sm-CMDTPA-Tyr3-octreotide in tumor-bearing rats[J]. Nucl Med Biol, 2001, 28(1):327-334.
30 Bohuslavizki KH. Somatostatin receptor imaging:current status and future perspectives[J]. J Nucl Med, 2003, 42(3):1057-1058.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]